1. Home
  2. RHI vs ADPT Comparison

RHI vs ADPT Comparison

Compare RHI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

N/A

Current Price

$41.90

Market Cap

4.3B

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$29.19

Market Cap

4.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RHI
ADPT
Founded
1948
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
RHI
ADPT
Price
$41.90
$29.19
Analyst Decision
Hold
Strong Buy
Analyst Count
11
8
Target Price
★ $39.56
$32.57
AVG Volume (30 Days)
2.0M
★ 2.0M
Earning Date
10-22-2026
11-04-2026
Dividend Yield
★ 5.62%
N/A
EPS Growth
N/A
★ 63.89
EPS
★ 0.90
N/A
Revenue
★ $5,378,506,000.00
$276,976,000.00
Revenue This Year
N/A
$10.85
Revenue Next Year
$3.95
$21.60
P/E Ratio
$46.59
★ N/A
Revenue Growth
N/A
★ 54.77
52 Week Low
$21.83
$12.00
52 Week High
$47.14
$32.21

Technical Indicators

Market Signals
Indicator
RHI
ADPT
Relative Strength Index (RSI) 54.08 58.55
Support Level $35.08 $24.02
Resistance Level $42.25 $29.92
Average True Range (ATR) 1.58 1.83
MACD -0.19 0.35
Stochastic Oscillator 17.03 60.05

Price Performance

Historical Comparison
RHI
ADPT

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: